Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 222

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome

Open access
van Bommel, Erik J.M., Muskiet, Marcel H.A., Tonneijck, Lennart, Kramer, Mark H.H., Nieuwdorp, Max, van Raalte, Daniel H. · 2017 · Clinical Journal of the American Society of Nephrology

Abstract

Diabetic kidney disease not only has become the leading cause for ESRD worldwide but also, highly contributes to increased cardiovascular morbidity and mortality in type 2 diabetes. Despite increased efforts to optimize renal and cardiovascular risk factors, like hyperglycemia, hypertension, obesity, and dyslipidemia, they are often insufficiently controlled in clinical practice. Although current drug interventions mostly target a single risk factor, more substantial improvements of renal and cardiovascular outcomes can be expected when multiple factors are improved simultaneously. Sodium-glucose cotransporter type 2 in the renal proximal tubule reabsorbs approximately 90% of filtered glucose. In type 2 diabetes, the maladaptive upregulation of sodium-glucose cotransporter type 2 contributes to the maintenance of hyperglycemia. Inhibiting these transporters has been shown to effectively improve glycemic control through inducing glycosuria and is generally well tolerated, although patients experience more genital infections. In addition, sodium-glucose cotransporter type 2 inhibitors favorably affect body weight, BP, serum uric acid, and glomerular hyperfiltration. Interestingly, in the recently reported first cardiovascular safety trial with a sodium-glucose cotransporter type 2 inhibitor, empagliflozin improved both renal and cardiovascular outcomes in patients with type 2 diabetes and established cardiovascular disease. Because the benefits were seen rapidly after initiation of therapy and other glucose-lowering agents, with the exception of liraglutide and semaglutide, have not been able to improve cardiovascular outcome, these observations are most likely explained by effects beyond glucose lowering. In this mini review, we present the drug class of sodium-glucose cotransporter type 2 inhibitors, elaborate on currently available renal and cardiovascular outcome data, and discuss how the effects of these agents on renal physiology may explain the data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.06080616

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 222

Metadata

Authors
van Bommel, E. J. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Nieuwdorp, M., & van Raalte, D. H.
Venue
Clinical Journal of the American Society of Nephrology
Published
2017-03-02
Volume
12
Issue
4
Pages
700-710
ISSN
  • 1555-9041 (ISSN-L)
  • 1555-905X
OpenAlex
W2591873133
Cited by
222
References
11
FWCI
18.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome. https://app.cochat.ai/papers/10.2215/cjn.06080616
The paper
van Bommel, E. J. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Nieuwdorp, M., & van Raalte, D. H. (2017). SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.06080616

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.